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Several studies have reported the use of fibrinolytic therapy
to re-establish the patency of arterio-venous shunts and fistulas
in patients undergoing chronic maintenance hemodialysis [1—7].
In recent years the indwelling Hickman central—venous catheter
has been employed as a temporary or permanent access device
in patients when more conventional access becomes impossible
or when immediate needs for dialysis preclude other alterna-
tives [81. As with other forms of vascular access, thrombosis
and infection remain common problems with these newer
devices [9—13].
Streptokinase and urokinase infused directly into the catheter
have been used to re-establish flow in patients with occluded
single and double lumen catheters placed to administer cancer
chemotherapy and parenteral hyperalimentation [11, 12, 14].
Hurtubise et a! [11] used low dose instillation of 150 IU of
streptokinase directly into the lumen and reported no adverse
reactions; however, catheters remained in place for a mean
duration of only 29 days and recurrent courses were not
mentioned. Zajko et a! [12] used continuous infusions of 3000
lU/hour for twelve to 24 hours. Two of his patients had
recurrent clotting episodes and developed mild skin reactions
with a second exposure to streptokinase. While there is no
evidence to indicate that streptokinase antigenicity and bleed-
ing complications are dose related [15], an ideal regimen should
deliver the minimum dose required to produce clot lysis and at
the same time limit systemic exposure. Guidelines for fibnno-
lytic therapy with occluded central venous catheters are limited
[11, 12, 14]. There is no information about the use of
streptokinase in hemodialysis patients with occluded catheters,
nor has its repeated use for recurrent loss of patency been
reported.
In our experience, using "low—dose" continuous infusions of
streptokinase directly into the central venous catheter have
been successful in re-establishing catheter patency in a high
percent of treated patients with few side effects and an apparent
minimal risk of sensitization. We present here the use of this
technique in nine patients with multiple recurrent episodes of
catheter occlusion over a three year period.
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Methods
Between August 1982 and June 1985, permanent single—lu-
men (Hickman), central venous catheters were surgically im-
planted in 51 patients at the University of Maryland Hospital as
previously described [8] for the purpose of performing long—
term maintenance hemodialysis. Office ifies and hospital and
dialysis records for all patients were reviewed retrospectively
to identify multiple episodes of catheter occlusion treated with
streptokinase, the dose, duration and method of streptokinase
infusion, the outcome of infusion and adverse effects of
fibrinolytic therapy.
Catheter occlusion was defined as either the inability to
obtain a continuous blood return through the catheter with
syringe aspiration or the inability to establish a minimum blood
flow rate on hemodialysis of at least 100 mI/minute, whether or
not saline could be infused through the catheter. Because
proper catheter function is often affected by the patient's
position as well as intravascular volume contraction, each
patient was carefully repositioned and, when appropriate, was
administered 100 to 300 ml of dextran for volume expansion
before the catheter was considered to be nonfunctional. Radio-
graphic contrast studies were not performed to confirm a
diagnosis of catheter thrombosis.
All patients were admitted to the nephrology ward service of
the University of Maryland Hospital for treatment. Routine
blood work (complete blood count, white blood cell differential
count, PT, PTT and platelet count) was obtained on each
patient prior to treatment with streptokinase. Each infusion was
continued for a duration of six to 14 hours. The catheter was
then tested for patency by either a hemodialysis nurse or an
experienced ward nurse by aspirating with a 20 ml syringe.
Hemodialysis was initiated immediately if patency was re-
established; otherwise the infusion was continued for another
12 hours and the procedure repeated. When catheter patency
could not be reestablished after 48 hours of infusion, the
treatment was considered to be unsuccessful and the access
replaced.
Streptokinase was administered with an intravenous infusion
pump in 5% dextrose solution delivered through the catheter at
a rate of 1000 to 2000 IU in 10 ml/hr. Two patients had two
clotting episodes each in which a bolus injection of 1000 to 2000
IU of streptokinase was administered prior to the i.v. infusion.
No other thrombolytic procedures were performed concomi-
1210
Catheter occlusion treatment 1211
Table 1. Dosing parameters for 9 patients with multiple episodes of central venous catheter thrombosis
Patient
No. of
clotting
episodes
Average dose!
exposure
x iO IU
Range
x 10
IU
Cumulative
dose!patient
X 10 IU
Mean duration
of exposure
—__hours
Range
hours
B.L. 6 20 12—60 120 18 12—48
C.G. 4 15 12—24 60 12 12
P.N.a 3 11 10—12 33 8.3 6—12
A.K.a 2 18 12—24 36 18 23—24
2 12 12 24 12 12
F.B.a.C 4 23.5 12—48 94 20.5 12—36
C.T. 2 12.5 12—13 25 11.5 11—12
C.M.a 2 18 12—24 36 12 12
V.F. 3 21 15—24 63 17 12—24
Mean SD 3.1 1.4 16.8 5.6 — 54.6 34.0 14.4 4.1 —
Range 2—6 11—23.5 — 24—120 6—48 —
a Tested for anti-streptokinase antibody
b Developed fever at end of second exposure (Tmax = 101.2)
Patency not re-established after fourth episode of thrombosis
tantly, and anticoagulants were not given routinely unless the
patient had been on maintenance therapy prior to catheter
occlusion. Coagulation studies were not routinely obtained
following the streptokinase infusions.
Routine catheter care between treatments was performed
using a standard protocol originally developed by the Univer-
sity of Maryland Cancer Center for catheters used to permit
chemotherapy and parenteral hyperalimentation in oncology
patients. At the end of dialysis, the catheter is infused with 3 ml
of heparin (1000 units/ml) and capped. Every 24 hours between
treatments the catheter is aspirated and reinfused with heparin
by the patient, a trained family member or a visiting nurse.
Antibody to streptokinase was tested by Ouchterlony immu-
nodiffusion in six of the nine patients after receiving multiple
infusions for recurrent thrombosis. Serum for antibody was
obtained two to 11 months after the last occlusive episode in
five patients. In the sixth patient (L.B., Table 1), serum was
obtained four weeks alter the first episode and 24 hours after the
second at the time of a temperature elevation.
Results
Between August 1982 and June 1985, catheter occlusion
occurred in 25.5% (13 patients) of all patients with permanently
implanted central venous catheters. Nine patients had more
than one episode (Table 1) with a mean of 3.1 episodes/patient.
The mean dose of streptokinase administered per episode was
16,800 lU/patient (range 10 to 60,000) and the mean cumulative
dose of streptokinase was 54,555 lU/patient (range 24 to
120,000). The mean duration of infusion for each episode was 15
hours (range 6 to 48).
The mean duration between episodes of catheter occlusion
was 4.2 5.9 months (range 22 days to 14 months), and the
mean duration from the initial insertion of the catheter to the
first episode was 5.2 8.9 months (range 15 days to 28 months)
for the 13 catheters inserted in these nine patients.
Hemodialysis was successfully reinstituted in 27 of 28 epi-
sodes (96.4%) following streptokinase infusion, and all patients
achieved blood flow rates of at least 200 ml/min on dialysis. One
patient (L.B.) developed a fever to 101.2 without another
source following his second exposure to streptokinase (Table
1), however no other adverse reactions were observed. No
patients developed clinically—obvious bleeding disorders or
pulmonary emboli, and skin rashes were not seen. Antibody to
streptokinase was not detected in the plasma of any of six
patients tested after their last exposure to streptokinase.
Discussion
Bleeding, fever and allergic reactions are the most common
complications following fibrinolytic therapy [11, 15]. Fever has
been reported in up to 25% of patients receiving streptokinase
and minor allergic reactions including skin rashes, in 6% [15].
Although reports of anaphylaxis are rare, pretreatment with
hydrocortisone has been recommended to avoid potential prob-
lems [15—17]. Sharma et al advise that repeat applications be
deferred for six to 12 months after an initial course because of
its antigenicity [15].
Permanent central venous catheters are being employed more
frequently as long—term vascular access for hemodialysis, par-
ticularly in individuals where multiple conventional accesses
have failed. Loss of function from catheter occlusion is a
common problem with these devices and occurred in over 25%
of our patients over a 27 month period. This rate is similar to
that reported for catheters placed for cancer chemotherapy
[11—13] and parenteral hyperalimentation [14].
No attempt was made radiographically to conclusively estab-
lish the presence of total or partial catheter thrombosis. The
diagnosis was made clinically in each case after conventional
maneuvers used to restore blood flow failed. Indeed, angiogra-
phy may be of limited value in this setting because of the well
reported development of fibrin sheaths around chronic indwell-
ing catheters [10].
Recurrent episodes of catheter occlusion occurred in nine
patients (17.6%) with a mean interval of 4.2 months between
episodes. In these patients, low doses of streptokinase infused
at a rate of 1000 to 2000 lU/hour over periods ranging from six
to 48 hours were effective in restoring catheter patency in over
96% of cases. These doses were well tolerated with no clinical-
ly—apparent bleeding complications or pulmonary emboli ob-
served. Fever occurred in only one case and no skin rashes
developed. In our limited experience using pharmacologic
fibrinolytic therapy with subclavian catheters and a much more
extensive, fourteen year experience using balloon catheters to
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declot arteriovenous hemodialysis cannulae, no patient has
developed overt pulmonary embolism, although we accept that
subclinical embolization is likely a not infrequent occurrence.
Based upon this experience, we do not feel that routine evalu-
ation for subclinical embolic phenomena is necessary or indi-
cated.
When tested by immunodiffusion, anti-streptokinase anti-
body was not detected in any of six patients receiving a
maximum cumulative dose of 94,000 IU, including the one
patient who developed a febrile reaction after his second
exposure to streptokinase.
Each of the patients reported here was hospitalized to mon-
itor therapy. Because of these encouraging results, it may be
possible to administer streptokinase infusions in an outpatient
setting using larger doses over a shorter interval to avoid the
cost of overnight hospital stays. We are currently evaluating
such a protocol.
We conclude that repeated applications of streptokinase in
the dose range described here are effective and well tolerated.
We do not feel that pretreatment with corticosteroids or routine
monitoring of coagulation studies is necessary.
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